You can access the annual and quarterly cash flow statements of LakeShore Biopharma Co Ltd to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2024H2
FY2024H1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---149.40M
---145.83M
Net income from continuing operations
---258.94M
---174.52M
Operating gains losses
--102.49M
--19.93M
Deferred tax
---20.91M
---820.35K
Other non-cash items
--59.51M
--18.47M
Change in working capital
---43.75M
---2.04M
-Change in receivables
---14.44M
--28.34M
-Change in inventory
---48.14M
---38.12M
-Change in prepaid expenses
--17.15M
---22.44M
-Change in other current liabilities
---2.46M
---1.15M
Cash from non-recurring investing activities
Cash from operating activities
---149.40M
---145.83M
Investing cash flow
Net cash from continuing investing activities
--20.83M
--23.42M
Capital expenditures
--20.83M
--23.58M
Net cash flow from disposal of fixed assets
--20.83M
--23.42M
Net cash flow from intangible asset transactions
--0.00
--0.00
Cash from non-current investing activities
Net cash flow from investing activities
---20.83M
---23.42M
Financing cash flow
Cash flow from continuous financing activities
--160.41M
--44.86M
Net cash flow from debt Issuance/repayment
---123.79M
--44.86M
Net cash flow from common stock issuance/repurchase
--284.20M
----
Net cash from non-recurrent financing activities
Net cash from financing activities
--160.41M
--44.86M
Net cash flow
Beginning cash balance
--259.91M
--370.37M
Current period cash flow changes
---13.35M
---110.46M
Effect of exchange rate changes
---3.53M
--13.93M
Ending cash balance
--246.55M
--259.91M
Free cash flow
---170.23M
---169.41M
Currency unit
USD
USD
Audit opinions
--
--
FAQs
What is the cash flow statement?
This report tracks the movement of cash into and out of the business, covering operating, investing, and financing activities. It highlights how well the company manages cash to support growth and meet its obligations.